Sermorelin — Research Dossier
Evidence grading
Structure
GHRH(1-29)
29 amino acids — minimal fully active GHRH fragment
FDA approval (Geref)
1997
Pediatric GH deficiency; approved by FDA
Withdrawn (commercial)
2008
Not safety-driven; 503A compounding use continues
WADA status
Prohibited
Category S2 — GH and related substances
Sermorelin is the only GHRH analogue with a former FDA approval — withdrawn in 2008 for commercial rather than safety reasons — giving it a regulatory pedigree no other injectable secretagogue in this category can match.
Sermorelin acetate is a synthetic peptide reproducing the first 29 amino acids of endogenous human growth hormone-releasing hormone — the minimal fragment sufficient for full GHRH receptor activation. Developed by EMD Serono under the brands Geref and Geref Pediatric, it was FDA-approved in 1997 for diagnosis and treatment of growth hormone deficiency in children, having earlier been approved as a diagnostic agent for adult GHD assessment.
The manufacturer withdrew sermorelin from the US market in 2008 for commercial rather than safety reasons, ending its status as a finished-drug product. It consequently occupies an unusual position: former FDA approval without current regulatory standing, distinguishing it from secretagogues that were never approved at all.
“Daily subcutaneous sermorelin produced meaningful height-velocity increases in children who responded to GHRH stimulation; transient injection-site reactions were the most common adverse event — the dataset underlying FDA approval in 1997.”
— FDA Medical Review, Geref Pediatric (sermorelin acetate)
Mechanism
Sermorelin binds the GHRH receptor (GHRHR) on anterior-pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous GH. Critically, its action remains subject to negative feedback via somatostatin: when GH rises, somatostatin release limits further secretion. This built-in brake distinguishes it pharmacologically from exogenous recombinant GH (somatropin), which delivers hormone directly and bypasses the feedback loop.
Sermorelin is rapidly degraded in plasma, giving a short half-life. The GH pulses it triggers are physiological in pattern — pulsatile and subject to normal regulatory control — rather than the sustained, supraphysiological elevation associated with direct GH administration.
Clinical evidence base
Pediatric GH deficiency (approval-grade)
The trials supporting original approval showed daily subcutaneous sermorelin produced meaningful height-velocity increases in children who responded to GHRH stimulation — effect sizes smaller than direct recombinant GH but with milder adverse-effect profiles. The most common treatment-related adverse event in the clinical trial programme was transient injection-site pain, redness, or swelling (~16% of patients), per the FDA medical review.
Adult GH optimisation (off-label/extrapolated)
Use in ageing adults to restore more youthful GH/IGF-1 pulsatility is off-label and supported by smaller studies and mechanistic rationale rather than large registrational trials. This application is not covered by the original approval and should be distinguished from the paediatric GHD dataset.
Regulatory and anti-doping status
Sermorelin is not currently an FDA-approved drug — approval lapsed with the 2008 market withdrawal — but retains a stronger regulatory pedigree than never-approved secretagogues. In the US it is available through 503A compounding pharmacies. It is not MHRA-approved; material supplied for laboratory work is research-use only in the UK. GHRH analogues including sermorelin are prohibited by WADA under category S2.
Evidence grade
Approved (lapsed) for paediatric GHD. The GHRHR mechanism is well-characterised and the paediatric indication was supported by standard pharmaceutical trial data. The broader anti-ageing and body-composition applications frequently marketed elsewhere rest on weaker evidence; long-term controlled data in healthy adults are limited.
References
- 1
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999.
- 2
US FDA. Geref / Geref Diagnostic / Geref Pediatric — approval and medical review documentation (sermorelin acetate, GHRH 1-29). FDA Drug Approval Package. 1997. https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020782.cfm
- 3
Thorner MO, et al. Sermorelin: a review of its use in growth hormone deficiency. J Clin Endocrinol Metab. 1997.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
